ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 321

Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis

EM Lewiecki1, S Horlait2, T Blicharski3, S Goemaere4, K Lippuner5, P Meisner6, PD Miller7, A Miyauchi8, J Maddox9, NS Daizadeh9 and A Grauer9, 1New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 2Amgen Ltd., Uxbridge, United Kingdom, 3Medical University of Lublin, Lublin, Poland, 4Ghent University Hospital, Gent, Belgium, 5Bern University Hospital, Bern, Switzerland, 6UCB Pharma, Brussels, Belgium, 7Colorado Center for Bone Research, Lakewood, CO, 8Miyauchi Medical Center, Osaka, Japan, 9Amgen Inc., Thousand Oaks, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Bone density, clinical trials, osteo-anabolics, osteoporosis and treatment

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 13, 2016

Session Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Treatment with romosozumab (Romo) has been shown to rapidly increase BMD in postmenopausal women with low BMD through a dual effect on bone, increasing bone formation and decreasing bone resorption (McClung NEJM 2014), and is being investigated for anti-fracture efficacy in postmenopausal women with osteoporosis. Here we report the results of the primary analysis of a phase 3 placeBo-contRolled study evaluatIng the efficacy anD safety of Romo in treatinG mEn with osteoporosis (BRIDGE; NCT02186171).  

Methods: This randomized, double-blind, multicenter study enrolled ambulatory men age 55–90 with a lumbar spine (LS), total hip (TH), or femoral neck (FN) T‑score ≤ –1.5 and a history of fracture after age 45, or a T‑score ≤ –2.5. Men were randomized 2:1 to receive Romo 210 mg or placebo (Pbo) SC once monthly for 12 months. All subjects received daily calcium and vitamin D. The primary endpoint was the percentage change from baseline in LS BMD by dual x-ray absorptiometry (DXA) at month 12. Secondary and exploratory endpoints included the percentage change from baseline in BMD by DXA at months 6 (LS, TH, and FN) and 12 (TH and FN), and the percentage change from baseline in the serum bone turnover markers P1NP and CTX, respectively. Safety endpoints included incidence of adverse events (AEs).  

Results: A total of 245 men were enrolled (163 Romo, 82 Pbo). Subjects had a baseline mean (SD) age of 72 (7.3) years, baseline mean LS, TH, and FN T-scores of –2.3, –1.9, and –2.3, respectively, and 54% had a historical fracture. In the Romo group, statistically significant gains in BMD from baseline were observed at all sites evaluated at months 6 and 12 (month 12: LS [12.1%] [Figure], TH [2.5%], and FN [2.2%]) (all P < 0.05 vs Pbo). Romo treatment also resulted in a rapid and transient increase in the bone formation marker P1NP that peaked at month 1 (median increase from baseline 86%) and gradually returned toward baseline. The bone resorption marker CTX decreased after the first dose of Romo, with the greatest decrease observed at month 1 (median decrease from baseline 31%), and remained below baseline through month 12. The overall subject incidence rates of AEs and serious AEs were balanced between treatment groups. Injection site reactions were reported in 5.5% and 3.7% of subjects in the Romo and Pbo groups, respectively; most reactions were reported as mild in severity. The subject incidence of positively adjudicated cardiovascular serious AEs was 4.9% (8/163) in the Romo group and 2.5% (2/81) in the Pbo group. The subject incidence of positively adjudicated cardiovascular death was 0.6% (1/163) in the Romo group and 1.2% (1/81) in the Pbo group.  

Conclusion: In men with osteoporosis, treatment with Romo for 12 months demonstrated a dual effect by increasing bone formation and decreasing bone resorption resulting in significant gains in BMD at the spine and the hip compared with Pbo, and was generally well tolerated.      

 


Disclosure: E. Lewiecki, Amgen Inc., Lilly, Merck, 2,Alexion, Amgen Inc., Lilly, Merck, Shire, 5,Shire, 8; S. Horlait, Amgen Inc., 1,Amgen Inc., 3; T. Blicharski, None; S. Goemaere, Amgen Inc., 8; K. Lippuner, None; P. Meisner, Eligible for UCB Pharma LTI, 1,UCB Pharma Brussels, 3; P. Miller, Alexion, Amgen, Boehringer Ingelheim, Immunodiagnostics, Eli Lilly & Company, Merck, Merck Serrano, National Bone Health Alliance, Novartis, Radius Pharma, Roche Diagnostics, Regeneron, Daiichi Sankyo, Inc. Ultragenyx, 2,Amgen, AgNovos, Lilly, Merck, Radius Pharma, Roche, Ultragenyx, 9,Allergan Pharmaceuticals, GrĂ¼nenthal Group, 9; A. Miyauchi, Amgen Inc., Astellas, BioPharma K.K, 5; J. Maddox, Amgen Inc., 1,Amgen Inc., 3; N. Daizadeh, Amgen Inc., 1,Amgen Inc., 3; A. Grauer, Amgen Inc., 1,Amgen Inc., 3.

To cite this abstract in AMA style:

Lewiecki E, Horlait S, Blicharski T, Goemaere S, Lippuner K, Meisner P, Miller P, Miyauchi A, Maddox J, Daizadeh N, Grauer A. Results of a Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Romosozumab in Men with Osteoporosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/results-of-a-phase-3-clinical-trial-to-evaluate-the-efficacy-and-safety-of-romosozumab-in-men-with-osteoporosis/. Accessed January 27, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/results-of-a-phase-3-clinical-trial-to-evaluate-the-efficacy-and-safety-of-romosozumab-in-men-with-osteoporosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.